4 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Kevin Coker of Proxima CRO, Gaurab Chakrabarti of Solugen, and Phil Sitter and Chris Chomenko of RepeatMD. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to four local innovators across industries — from marketing tech to synthetic biology — recently making headlines in Houston innovation.

Kevin Coker, CEO and co-founder of Proxima CRO, and Gaurab Chakrabarti, CEO and co-founder of Solugen

First Bight VC named two Houstonians to its board. Photos courtesy

First Bight Ventures, a new VC firm focused exclusively on early-stage synthetic biology startups founded by Veronica Wu in January, has named two new board members: Gaurab Chakrabarti, co-founder and CEO of Solugen, and Kevin Cocker, co-founder and CEO of Proxima CRO.

"We are excited to announce the addition of Dr. Gaurab Chakrabarti and Kevin Cocker," Wu says in a press release. "These two advisors are experts in their respective fields of medicine and biotechnology. They are proven leaders of Houston-based companies, which is key to our overall growth strategy, as we seek to establish Houston as a geographic center for innovation in Synthetic Biology." Click here to read more.

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko join the Houston Innovators Podcast to explain how they are revolutionizing the aesthetics industry. Photos courtesy

Houston restaurateur pivoted his restaurant marketing business amid the pandemic — to a growing industry: aesthetics. Phil Sitter took the idea and tech he created with VIPInsiders to launch RepeatMD, a customizable marketing and fintech platform focused on the aesthetics industry, which includes plastic surgeons, dermatologists, etc.

Sitter, who serves as the company's CEO, says once he dived into learning about the industry, he found out these types of business are seeing incredible growth following the pandemic.

"They call it the 'Zoom boom' — everyone saw themselves on Zoom daily and decided to invest in themselves and their facial treatments." says Chris Chomenko, vice president of sales for the company, on the Houston Innovators Podcast.

"And they had the time," Sitter adds. "When you think about aesthetic procedures — whether its invasive or non-invasive, it takes time for recovery." Click here to read more.

RepeatMD's CEO Phil Sitter and Vice President of Sales Chris Chomenko join the Houston Innovators Podcast to explain how they are revolutionizing the aesthetics industry. Photos courtesy

Houston innovators find 'perfect storm' for fintech and marketing platform

Houston innovators podcast episode 129

Phil Sitter saw fast growth and adoption from his restaurant rewards platform he founded in 2019, but when the pandemic hit, he had to go back to the drawing board to find a growing industry that needed to be disrupted by his technology. And he did.

Sitter, a Houston restaurateur, originally founded VIPInsiders to help his restaurants — and later, licensing the technology out, other Houston eateries too — reward loyal patrons who continue to come in. However, in 2020, Sitter considered a pivot.

"We realized the restaurant industry may never be the same, and we asked ourselves who could be an ideal client," Sitter says on the Houston Innovators Podcast.

This pivot ended up creating RepeatMD, a customizable marketing and fintech platform focused on the aesthetics industry, which includes plastic surgeons, dermatologists, etc.

Sitter, who serves as the company's CEO, says once he dived into learning about the industry, he found out these types of business are seeing incredible growth following the pandemic.

"They call it the 'Zoom boom' — everyone saw themselves on Zoom daily and decided to invest in themselves and their facial treatments." says Chris Chomenko, vice president of sales for the company.

"And they had the time," Sitter adds. "When you think about aesthetic procedures — whether its invasive or non-invasive, it takes time for recovery."

After initially branching out into the field, Sitter says they are now onboarding up to 200 new locations a month, providing med spas around the world the ability to reward returning customers, as well as inform them on the breadth of options the facility offers. RepeatMD has expanded its team to 50 people and is eyeing seed funding this summer.

"Some things had to work out perfectly in order," Chomenko says, "for this perfect storm of perfect timing. Whenever you talk about entrepreneurs and how much of it was luck and how much of it is hard work, we really have attribute a lot of our success to being there with the right idea, in the right place, at the right time."

Sitter and Chomenko share more about the future of RepeatMD on the podcast episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

RepeatMD offers its clients rewards-based software and is expanding with a new fintech tool. Photo via Getty Images

Fast-growing Houston software startup expands with fintech model

innovative marketing

A less than one-year-old B2B software startup in Houston is beefing up its offerings with a new feature that thrusts it into the rapidly growing fintech space.

RepeatMD, founded in December 2020, specializes in white-label rewards apps for plastic surgeons, medical spas, dermatologists, and similar businesses. Now, it's expanding into the "buy now, pay later" fintech realm through a new deal with BTL Industries, a Marlborough, Massachusetts-based provider of body-sculpting equipment.

RepeatMD's new Medical Gym function enables customers treated with BTL equipment to finance add-on enhancement and maintenance packages through "buy now, pay later" (BNPL) arrangements. BNPL is a booming sector. The size of the global BNPL market approached $90.7 billion in 2020 and is projected to come close to $4 trillion by 2030, according to Allied Market Research.

RepeatMD essentially layers the Medical Gym's BNPL functionality on top of the rewards feature of its apps.

Chris Chomenko, vice president of sales at RepeatMD, says the startup already had been working on a BNPL offering when BTL approached the RepeatMD team about creating a BNPL product. RepeatMD and BTL share many of the same clients.

"We are rolling out with them nationally at a breakneck speed because the demand they have from their client base is so high," Chomenko says. "It's kind of forcing us to do in three months what we planned on doing in three years."

While the concept of a rewards app or a BNPL program is not unique, their pairing is, according to Chomenko. Sitter calls the marriage of the two a "game changer" — a game changer that eventually should extend well beyond BTL's clients.

RepeatMD founder and CEO Philipp Sitter says the Medical Gym feature lets customers break up the cost of, say, a $5,000 treatment into management monthly payments. The results of a survey of RepeatMD app users found that the guilt of putting down a wad of cash on aesthetics services was the No. 2 barrier cited in terms of spending money on treatments.

"What we'll be working on is being a full, proper fintech play, where we have that buy now, pay later functionality, and doctors can get paid in advance for treatments. But that is a large endeavor that will take us all of a year to [complete]," Chomenko says.

RepeatMD counts more than 600 practices in North America as customers. The startup envisions that figure rising to 1,000 by the end of this year. In tandem with that growth, RepeatMD foresees revenue climbing to eight figures (at least $10 million) by the end of 2022 and its valuation growing to nine figures (at least $100 million) by then.

Today, RepeatMD employs about 30 people. Sitter says the headcount should reach 75 to 100 by the end of next year.

Sitter is self-funding RepeatMD with proceeds from other business ventures, including Houston-based food and beverage loyalty and rewards platform VIPinsiders and Houston-based brunch and lunch restaurant EggHaus Gourmet. However, RepeatMD plans to raise outside capital in the first quarter of 2022.

The company sets up each client with an exclusive private-label app. RepeatMD says businesses using its app have seen an average sales increase of $313,000 and an average of 51 new referrals within the first 90 days of adopting the app.

Sitter says the RepeatMD rewards app provides a "gateway" for businesses to drum up repeat business and sell more services, much like the Starbucks rewards app incentivizes customers to try different food and beverage products.

"We see us becoming ubiquitous in the industry, where anybody that's a dermatologist, a plastic surgeon, or a medical spa has [our app]," Sitter says.

"We look at mobile app experience as something that's coming for all the local businesses. We're just the frontrunners in bringing it to the masses," he adds.

Philipp Sitter is the founder of RepeatMD. Photo via LinkedIIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New UH survey reveals concerns over AI data center growth in Houston

data findings

A new report out of the University of Houston shows that area residents remain wary of the long-term effects of operating data centers.

The recent survey from the University of Houston’s latest SPACE City Panel, conducted by the Center for Public Policy at the Hobby School of Public Affairs, shows that while 85 percent of Houston-area residents use AI, nearly 63 percent oppose the construction of AI data centers within 1 mile of their homes.

Respondents’ concerns centered around data centers’ high energy demand and the area’s power grid reliability. According to the survey, 32 percent of residents who oppose local data center projects would be more likely to support the centers if they relied on renewable energy over fossil fuels.

“Respondents understand that AI can bring economic and educational benefits, but they are also concerned about the physical infrastructure needed to fuel AI, especially data centers,” Soran Mohtadi, post-doctoral fellow at the Hobby School and a researcher on the report, said in a news release. “This physical infrastructure demands more electricity and water, leading to environmental impacts.”

Experts estimate that 6.5 gigawatts of data center capacity will be added to the Texas grid by 2030. And Houston’s data center capacity is predicted to more than double by 2028.

The Electric Reliability Council of Texas also projects electricity demand could reach 218 gigawatts by 2031, which would be more than double the record peak set in August 2023. Data centers are expected to account for 86 gigawatts of that new demand.

Survey respondents also said they are concerned about the state's future water supply, given the large amounts of water that data centers need to stay cool.

In terms of who’s responsible for that issue, 57.6 percent of respondents said they put the onus on Texas lawmakers, while 31.5 percent say tech companies should be responsible.

Additionally, more than 75 percent of respondents believed that data center developers and technology companies—not residents—should bear the cost of infrastructure upgrades to support data centers.

“Every decision legislators make has implications on residents’ everyday lives and local infrastructure now and in the future,” Maria P. Perez Arguelles, lead researcher on the report and research assistant professor at the Hobby School, added in the news release. “This issue is going to become more important in years to come, so this is just the beginning.”

Read the full report here.

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."
View All Listings